Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: Effects of bolus and continuous administration

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 2943-2952

  Arosarena, Oneida A ^a   Del Carpio Cano, Fabiola E ^a   Dela Cadena, Raul A ^a   Rico, Mario C ^a   Nwodim, Emeka ^a   Safadi, Fayez F ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; GROWTH FACTOR; OSTEOACTIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BOLUS INJECTION; CELL DIFFERENTIATION; CONTINUOUS INFUSION; GENE EXPRESSION; HYDROGEL; MESENCHYME CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL LINE; DELAYED-ACTION PREPARATIONS; EYE PROTEINS; GENE EXPRESSION; HYDROGEL; MEMBRANE GLYCOPROTEINS; MESENCHYMAL STEM CELLS; MICE; OSTEOCALCIN;

MURINAE;

EID: 80051950500     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22639     Document Type: Article

References (67)

1. Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popoff SN, Safadi FF. 2007. Osteoactivin acts as a downstream mediator of BMP-2 effects on osteoblast function. J Cell Physiol 210: 26-37.
2. Abe H, Uto H, Takami Y, Hasuike S, Kodama M, Nagata K, Moriuchi A, Numata M, Ido A, Tsubouchi H. 2007. Transgenic expression of osteoactivin in the liver attenuates hepatic fibrosis in rats. Biochem Biophys Res Commun 356: 610-615.
3. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. 1994. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 269: 20126-20133.
4. American Academy of Orthopaedic Surgeons. 2008. Musculoskeletal injuries. In: The burden of musculoskeletal diseases in the United States: Prevalence, societal and economic cost. pp. 123-162.
5. Anderson MG, Smith RS, Savinova OV, Hawes NL, Chang B, Zabaleta A, Wilpan R, Heckenlively JR, Davisson M, John SW. 2001. Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice. BMC Genet 2: 1.
6. Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW. 2002. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 30: 81-85.
7. Anderson MG, Libby RT, Mao M, Cosma IM, Wilson LA, Smith RS, John SW. 2006. Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC Biol 4: 20.
8. Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S, Fujisawa Y. 1995. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210: 670-677.
9. Arden RL, Rachel JD, Marks SC, Dang K. 1999. Volume-length impact of lateral jaw resections on complication rates. Arch Otolaryngol Head Neck Surg 125: 68-72.
10. Bandari PS, Qian J, Yehia G, Joshi DD, Maloof PB, Potian J, Oh HS, Gascon P, Harrison JS, Rameshwar P. 2003. Hematopoietic growth factor inducible neurokinin-1 type: A transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regul Pept 111: 169-178.
11. Blackwell KE, Lacombe V. 1999. The bridging lateral mandibular reconstruction plate revisited. Arch Otolaryngol Head Neck Surg 125: 988-993.
12. Blom S, Holmstrup P, Dabelsteen E. 1994. A comparison of the effect of epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor on rat periodontal ligament fibroblast-like dells' DNA synthesis and morphology. J Periodontol 65: 373-378.
13. Boissy RE, Richmond B, Huizing M, Helip-Wooley A, Zhao Y, Koshoffer A, Gahl WA. 2005. Melanocyte-specific proteins are aberrantly trafficked in melanocytes of Hermansky-Pudlak syndrome-type 3. Am J Pathol 166: 231-240.
14. Boyd JB, Mulholland RS, Davidson J, Gullane PJ, Rotstein LE, Brown DH, Freeman JE, Irish JC. 1995. The free flap and plate in oromandibular reconstruction: Long-term review and indications. Plast Reconstr Surg 95: 1018-1028.
15. Brunberg E, Andersson L, Cothran G, Sandberg K, Mikko S, Lindgren G. 2006. A missense mutation in PMEL17 is associated with the Silver coat color in the horse. BMC Genet 7: 46.
16. Chung JS, Sato K, Dougherty II, Cruz PD, Jr., Ariizumi K. 2007. DC-HIL is a negative regulator of T lymphocyte activation. Blood 109: 4320-4327.
17. DeGroot J. 1998. Carriers that concentrate native bone morphogenetic protein in vivo. Tissue Eng 4: 337-341.
18. Dennison DK, Vallone DR, Pinero GJ, Rittman B, Caffesse RG. 1994. Differential effect of TGF-β1 and PDGF on proliferation of periodontal ligament cells and gingival fibroblasts. J Periodontol 65: 641-648.
19. Diefenderfer DL, Osyczka AM, Garino JP, Leboy PS. 2003. Regulation of BMP-induced transcription in cultured human bone marrow stromal cells. J Bone Jt Surg Am 85-A: 19-28.
20. Disher MJ, Esclamado RM, Sullivan MJ. 1993. Indications for the AO plate with a myocutaneous flap instead of revascularized tissue transfer for mandibular reconstruction. Laryngoscope 103: 1264-1268.
21. Garcia-Godoy F, Murray PE. 2006. Status and potential commercial impact of stem cell-based treatments on dental and craniofacial regeneration. Stem Cells Dev 15: 881-887.
22. Gazit D, Turgeman G, Kelley P, Wang E, Jalenak M, Zilberman Y, Moutsatsos I. 1999. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1: 121-133.
23. Geiger M, Li RH, Friess W. 2003. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 55: 1613-1629.
24. Goding JW. 1986. Immunofluorescence. In: Monoclonal antibodies: Principles and practice. Orlando: Academic Press. pp. 241-280.
25. Haidar ZS, Hamdy RC, Tabrizian M. 2009a. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A. Current challenges in BMP delivery. Biotechnol Lett 31: 1817-1824.
26. Haidar ZS, Hamdy RC, Tabrizian M. 2009b. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B. Delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett 31: 1825-1835.
27. Helip-Wooley A, Westbroek W, Dorward HM, Koshoffer A, Huizing M, Boissy RE, Gahl WA. 2007. Improper trafficking of melanocyte-specific proteins in Hermansky-Pudlak syndrome type-5. J Invest Dermatol 127: 1471-1478.
28. Hing KA. 2004. Bone repair in the twenty-first century: Biology, chemistry, or engineering? Philos Trans R Soc Lond A 362: 2821-2850.
29. Hoashi T, Muller J, Vieira WD, Rouzaud F, Kikuchi K, Tamaki K, Hearing VJ. 2006. The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers. J Biol Chem 281: 21198-21208.
30. Ikeda S, Hachisu R, Yamaguchi A, Gao YH, Okano T. 2000. Radiation retards muscle differentiation but does not affect osteoblastic differentiation induced by bone morphogenetic protein-2 in C2C12 myoblasts. Int J Radiat Biol 76: 403-411.
31. Jager E, Maeurer M, Hohn H, Karbach J, Jäger D, Zidianakis Z, Bakhshandeh-Bath A, Orth J, Neukirch C, Necker A, Reichert TE, Knuth A. 2000. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 86: 538-547.
32. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. 1994. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127: 1755-1766.
33. Kuan CT, Wakiya K, Dowell JM, Herndon JE II, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. 2006. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12: 1970-1982.
34. Leclerc N, Luppen CA, Ho VV, Nagpal S, Hacia JG, Smith E, Frenkel B. 2004. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 33: 175-193.
35. Lee M, Javed A, Kim H, Shin HI, Gutierrez S, Choi JY, Rosen V, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Ryoo HM. 1999. Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor β1 in C2C12 myogenic cell coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J Cell Biochem 73: 114-125.
36. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON. 1999. The effect of regional gene therapy with bone morphogenetic protein-2 producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81: 905-917.
37. Mao JJ, Giannobile WV, Helms JA, Hollister SJ, Krebsbach PH, Longaker MT, Shi S. 2006. Craniofacial tissue engineering by stem cells. J Dent Res 85: 966-979.
38. Nakamura A, Ishii A, Ohata C, Komurasaki T. 2007. Early induction of osteoactivin expression in rat renal tubular epithelial cells after unilateral ureteral obstruction. Exp Toxicol Pathol 59: 53-59.
39. Ogawa T, Nikawa T, Furochi H, Kosyoji M, Hirasaka K, Suzue N, Sairyo K, Nakano S, Yamaoka T, Itakura M, Kishi K, Yasui N. 2005. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am J Physiol Cell Physiol 289: C697-C707.
40. Okamoto I, Pirker C, Bilban M, Berger W, Losert D, Marosi C, Haas OA, Wolff K, Pehamberger H. 2005. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia 7: 303-311.
41. Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, Hori T, Hayash K, Tsubouchi H. 2003. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 39: 779-785.
42. Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M. 2003. Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem 278: 44305-44311.
43. Owen TA, Smock SL, Prakash S, Pinder L, Brees D, Krull D, Castleberry TA, Clancy YC, Marks SC, Jr., Safadi FF, Popoff SN. 2003. Identification and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaroyt Gene Expr 13: 205-220.
44. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, Huard J. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751-759.
45. Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT. 2006. BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21: 637-646.
46. Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jeffers ME, Lichenstein HS, LaRochelle WJ. 2007. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60: 423-435.
47. Raiche AT, Puleo DA. 2001. Triphasic release model for multilayered gelatin coatings that can recreate growth factor profiles during wound healing. J Drug Target 9: 449-460.
48. Raiche AT, Puleo DA. 2004. Cell responses to BMP-2 and IGF-I released with different time-dependent profiles. J Biomed Mater Res 69A: 342-350.
49. Reddi AH. 2000. Bone morphogenetic proteins and skeletal development: The kidney-bone connection. Pediatr Nephrol 14: 598-601.
50. Rifas L. 2007. The role of noggin in human mesenchymal stem cell differentiation. J Cell Biochem 100: 824-834.
51. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. 2007. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178: 6557-6566.
52. Risteli L, Risteli J. 1993. Biochemical markers of bone metabolism. Ann Med 25: 385-393.
53. Safadi FF, Xu J, Smock SL, Rico MC, Owen TA, Popoff SN. 2001. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem 84: 12-26.
54. Safadi FF, Xu J, Smock SL, Kanaan RA, Selim AH, Odgren PR, Marks SC, Jr., Owen TA, Popoff SN. 2003. Expression of connective tissue growth factor in bone: Its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J Cell Physiol 196: 51-62.
55. Salgado AJ, Coutinho OP, Reis RL. 2004. Bone tissue engineering: State of the art and future trends. Macromol Biosci 4: 743-765.
56. Selim AA. 2009. Osteoactivin bioinformatic analysis: Prediction of novel functions, structural features, and modes of action. Med Sci Monit 15: MT19-MT33.
57. Shikano S, Bonkobara M, Zukas PK, Ariizumi K. 2001. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 276: 8125-8134.
58. Song JJ, Aswad R, Kanaan RA, Rico MC, Owen TA, Barbe MF, Safadi FF, Popoff SN. 2007. Connective tissue growth factor (CTGF) acts as a downstream mediator of TGF-β1 to induce mesenchymal cell condensation. J Cell Physiol 210: 398-410.
59. Spector JA, Luchs JS, Mehrara BJ, Greenwald JA, Smith LP, Longaker MT. 2001. Expression of bone morphogenetic proteins during membranous bone healing. Plast Reconstr Surg 107: 124-134.
60. Toriumi DM, Kotler HS, Luxenberg DP, Holtrop ME, Wang EA. 1991. Mandibular reconstruction with a recombinant bone-inducing factor. Arch Otolaryngol Head Neck Surg 117: 1101-1112.
61. Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ. 2006. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12: 1373-1382.
62. Urist MR, DeLange RJ, Finerman GAM. 1983. Bone cell differentiation and growth factors. Science 220: 680-686.
63. Wang EA, Israel DI, Kelly S, Luxenberg DP. 1993. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9: 57-71.
64. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP. 1995. Nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 60: 73-81.
65. Woo BH, Fink BF, Page R, Schrier JA, Jo YW, Jiang G, DeLuca M, Vasconez HC, DeLuca PP. 2001. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 18: 1747-1753.
66. Yamamoto M, Takahashi Y, Tabata Y. 2003. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24: 4375-4383.
67. Yasumoto K, Watabe H, Valencia JC, Kushimoto T, Kobayashi T, Appella E, Hearing VJ. 2004. Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): Rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment. J Biol Chem 279: 28330-28338.